JP2016525530A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525530A5 JP2016525530A5 JP2016528534A JP2016528534A JP2016525530A5 JP 2016525530 A5 JP2016525530 A5 JP 2016525530A5 JP 2016528534 A JP2016528534 A JP 2016528534A JP 2016528534 A JP2016528534 A JP 2016528534A JP 2016525530 A5 JP2016525530 A5 JP 2016525530A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate
- acceptable salt
- pharmaceutically acceptable
- decitabine
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361858802P | 2013-07-26 | 2013-07-26 | |
| US61/858,802 | 2013-07-26 | ||
| PCT/EP2014/065937 WO2015011234A1 (en) | 2013-07-26 | 2014-07-24 | Volasertib in combination with decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525530A JP2016525530A (ja) | 2016-08-25 |
| JP2016525530A5 true JP2016525530A5 (https=) | 2018-07-12 |
Family
ID=51352490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528534A Pending JP2016525530A (ja) | 2013-07-26 | 2014-07-24 | 急性骨髄性白血病及び骨髄異形成症候群の処置のためのボラセルチブと組み合わせたデシタビン |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20150031642A1 (https=) |
| EP (1) | EP3024465A1 (https=) |
| JP (1) | JP2016525530A (https=) |
| KR (1) | KR20160037233A (https=) |
| CN (1) | CN105407893A (https=) |
| AU (1) | AU2014295018A1 (https=) |
| BR (1) | BR112015031397A8 (https=) |
| CA (1) | CA2919294A1 (https=) |
| CL (1) | CL2016000024A1 (https=) |
| EA (1) | EA201600133A1 (https=) |
| MX (1) | MX2016001084A (https=) |
| PH (1) | PH12016500059A1 (https=) |
| WO (1) | WO2015011234A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220718T1 (hr) | 2013-11-11 | 2022-09-30 | Amgen Inc. | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka |
| WO2019025256A1 (en) * | 2017-08-01 | 2019-02-07 | Bayer Aktiengesellschaft | COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS |
| CN113082211A (zh) * | 2021-04-14 | 2021-07-09 | 南方医科大学珠江医院 | 一种治疗npm1突变急性髓系白血病的药物组合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20070117776A1 (en) * | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
| US7439358B2 (en) * | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US9358233B2 (en) * | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
-
2014
- 2014-07-24 KR KR1020167005392A patent/KR20160037233A/ko not_active Withdrawn
- 2014-07-24 BR BR112015031397A patent/BR112015031397A8/pt not_active IP Right Cessation
- 2014-07-24 JP JP2016528534A patent/JP2016525530A/ja active Pending
- 2014-07-24 CA CA2919294A patent/CA2919294A1/en not_active Abandoned
- 2014-07-24 US US14/340,016 patent/US20150031642A1/en not_active Abandoned
- 2014-07-24 MX MX2016001084A patent/MX2016001084A/es unknown
- 2014-07-24 AU AU2014295018A patent/AU2014295018A1/en not_active Abandoned
- 2014-07-24 CN CN201480041933.3A patent/CN105407893A/zh active Pending
- 2014-07-24 WO PCT/EP2014/065937 patent/WO2015011234A1/en not_active Ceased
- 2014-07-24 EP EP14750704.0A patent/EP3024465A1/en not_active Ceased
- 2014-07-24 EA EA201600133A patent/EA201600133A1/ru unknown
-
2016
- 2016-01-07 CL CL2016000024A patent/CL2016000024A1/es unknown
- 2016-01-08 PH PH12016500059A patent/PH12016500059A1/en unknown
-
2017
- 2017-02-24 US US15/441,422 patent/US20170157159A1/en not_active Abandoned
-
2019
- 2019-04-16 US US16/385,130 patent/US20190240241A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2856646C (en) | Combination treatment of cancer | |
| Tolar et al. | Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels | |
| JP2019511488A5 (https=) | ||
| JP2015504871A5 (https=) | ||
| Niitsu et al. | A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2010500370A5 (https=) | ||
| JP2015505564A5 (https=) | ||
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| JP2020503269A5 (https=) | ||
| van Ramshorst et al. | Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study | |
| JP2019530706A5 (https=) | ||
| AU2017279592A1 (en) | Prophylactic or therapeutic agent for idiopathic inflammatory myopathies | |
| JP2020533302A5 (https=) | ||
| JP2016525530A5 (https=) | ||
| Axelsen et al. | Effects of 6-mercaptopurine in pressure overload induced right heart failure | |
| JP2017514858A5 (https=) | ||
| JP2014129405A5 (https=) | ||
| TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
| JP2017508737A5 (https=) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| Glowacki et al. | Osteoporosis and mechanisms of skeletal aging | |
| JP2018522881A5 (https=) | ||
| JP2016525530A (ja) | 急性骨髄性白血病及び骨髄異形成症候群の処置のためのボラセルチブと組み合わせたデシタビン | |
| JP2021511352A5 (https=) |